Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors

Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of a solid tumor which has
progressed on, or following standard therapy, or for which no standard effective
therapy is known.

- Children age 1-18 years.

Exclusion Criteria:

- Presence of active infection.

- Requirement to receive concurrent chemotherapy immunotherapy, radiotherapy, or any
other investigational drug while on study.

- Inadequate bone marrow, hepatic, or renal function.